EduHK 20220622-20220628

China Daily

News> Nation> Content
Published: 09:39, May 03, 2022 | Updated: 22:31, May 03, 2022
Chinese-made Omicron vaccine trials get going
By Zhang Zhihao
Published:09:39, May 03, 2022 Updated:22:31, May 03, 2022 By Zhang Zhihao

A doctor administers a vaccine targeted at the Omicron variant in Hangzhou, Zhejiang province, on May 1, 2022. (PHOTO BY ZHANG YUHUAN/CHINA NEWS SERVICE)

China began clinical trials for a vaccine designed specifically against the Omicron variant in Hangzhou, Zhejiang province, on Sunday, making it the first vaccine of its kind to enter human trials in the world against the highly transmissible COVID-19 strain.

The trial in China would consist of a randomized, double-blind study on people age 18 and older who have been inoculated with two or three doses of COVID-19 vaccines

China National Biotech Group, a subsidiary of Sinopharm, has been developing the vaccine since December 2021, the company said in a news release on Monday.

ALSO READ: Mainland reports 846 new local COVID-19 cases

The National Medical Products Administration approved the clinical trials for the vaccine on April 26. Three days later, the United Arab Emirates also gave the greenlight for clinical trials.

The trial in China would consist of a randomized, double-blind study on people age 18 and older who have been inoculated with two or three doses of COVID-19 vaccines.

Yang Xiaoming, chairman of China National Biotech Group, said in the launch ceremony of the vaccine's clinical trial the Omicron variant is highly transmissible and elusive. He hopes the new vaccine will achieve success and benefit people around the world.

ALSO READ: Multinationals express firm faith in China

Zhang Yuntao, the chief scientist at the company, said the Omicron vaccine entering clinical trial represents a major development in the fight against COVID-19 in China. The trial will examine the safety and potency of the vaccine, he added.


Share this story

CHINA DAILY
HONG KONG NEWS
OPEN
Please click in the upper right corner to open it in your browser !